Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Werewolf Therapeutics Inc (HOWL)

Werewolf Therapeutics Inc (HOWL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Werewolf Therapeutics Inc 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 USA

https://werewolftx.com P: 617-952-0555

Description:

Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.

Key Statistics

Overview:

Market Capitalization, $K 288,691
Enterprise Value, $K 187,011
Shares Outstanding, K 43,347
Annual Sales, $ 19,940 K
Annual Net Income, $ -37,370 K
Last Quarter Sales, $ 1,500 K
Last Quarter Net Income, $ -12,000 K
EBIT, $ -40,500 K
EBITDA, $ -38,680 K
60-Month Beta 0.70
% of Insider Shareholders 21.10%
% of Institutional Shareholders 64.84%
Float, K 34,201
% Float 78.90%
Short Volume Ratio 0.50

Growth:

1-Year Return 163.29%
3-Year Return -56.21%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.33 on 03/07/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -1.04
EPS Growth vs. Prev Qtr -43.48%
EPS Growth vs. Prev Year 15.38%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

HOWL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -32.25%
Return-on-Assets % -20.43%
Profit Margin % -187.41%
Debt/Equity 0.29
Price/Sales 14.67
Price/Cash Flow N/A
Price/Book 2.02
Book Value/Share 3.08
Interest Coverage -10.90
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar